Home Tags NV103

Tag: NV103

NanoValent Receives Patent for Targeted Polymerized Nanoparticles in Cancer Treatment

Danielle Garcia
NanoValent Pharmaceuticals, a development stage pharmaceutical company progressing a new class of therapeutic anti-cancer agents called targeted nanospheres (TNS), has received United States Patent...

NanoValent Pharmaceuticals and Children’s Hospital Los Angeles Sign Exclusive Global Licensing...

Sonia Portillo
Earlier today, NanoValent Pharmaceuticals, a privately-held development-stage cancer-focused pharmaceutical company advancing antibody-drug conjugate or ADC therapeutics, confirmed signing a licensing agreement with Children's Hospital...
ADC Review, Journal of Antibody-drug Conjugates
MADE POSSIBLE BY:
ADCBIO
Lonza
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policy makers.

Latest

Peer Review

© 2013-2019 Sunvalley Communication, LLC. All Rights Reserved.